Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality

BACKGROUND: The US Food and Drug Administration authorized COVID-19 convalescent plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access Program (EAP) and the Emergency Use Authorization (EUA), leading to use in about 500,000 patients during the first year of the pandemic for...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:eLife
Main Authors: Casadevall, Arturo, Dragotakes, Quigly, Johnson, Patrick W, Senefeld, Jonathon W, Klassen, Stephen A, Wright, R Scott, Joyner, Michael J, Paneth, Nigel, Carter, Rickey E
Formato: Artigo
Idioma:Inglês
Publicado: eLife Sciences Publications, Ltd 2021
Assuntos:
Epidemiology and Global Health
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8205484/
https://ncbi.nlm.nih.gov/pubmed/34085928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.69866
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares